Bronchiectasis in severe asthma and asthmatic components in bronchiectasis
- PMID: 34924307
- DOI: 10.1016/j.resinv.2021.11.004
Bronchiectasis in severe asthma and asthmatic components in bronchiectasis
Abstract
Asthma and bronchiectasis are different diseases; however, differentiating them can be difficult because they share several symptomatic and physiological similarities. Approximately 20% of patients with bronchiectasis have eosinophilic inflammation, 34% show wheezing, and 7-46% have comorbid asthma, although comorbidity with severe asthma may be limited as shown in 3.3% of cases of bronchiectasis. Meanwhile, 25-68% of patients with severe asthma have comorbid bronchiectasis, and at least two phenotypes are present in the accompanying bronchiectasis: eosinophilic bronchiectasis and chronic infectious bronchiolitis/bronchiectasis. Recent studies show that type-2-targeted biologics are effective for eosinophilic bronchiectasis and theoretically effective for some of the remaining cases when used before oral corticosteroids. Further studies are needed to identify treatment strategies for severe asthma with comorbid bronchiectasis and vice versa.
Keywords: Bronchiectasis; Chronic infectious bronchiolitis; Exhaled nitric oxide; Severe asthma.
Copyright © 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of Interest Dr. Matsumoto received lecturer fees from AstraZeneca K.K., Novartis Pharma K.K., GlaxoSmithKline K.K., Sanofi K.K., and KYORIN Pharmaceutical Co. Ltd. and research funding from Novartis Pharma K.K.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
